key: cord-1040454-x4nzf4fb
authors: Kluger, N.; Klimenko, T.; Bosonnet, S.
title: Herpes simplex, herpes zoster and periorbital erythema flares after SARS-CoV-2 vaccination: 4 cases
date: 2021-10-02
journal: Ann Dermatol Venereol
DOI: 10.1016/j.annder.2021.07.009
sha: 1f8b7c5f099262637372aec3493c6173dc942895
doc_id: 1040454
cord_uid: x4nzf4fb

nan

As of June 17, 2021, 21.1% of the world population has received at least one dose of any COVID-19 vaccine [1] . Dermatologists have rapidly witnessed an increasing number of cutaneous adverse events, especially "COVID-arm" [2, 3] . Cases of herpes zoster (HZ) have started to be published at an increasing rate very recently [4] [5] [6] [7] [8] [9] . McMahon et al reported 10 cases of herpes zoster (HZ) and four cases of herpes simplex virus (HSV) flares after Moderna and Pfizer vaccination [4] . Herein we report four additional cases, including two patients under biologics.

A 39-year-old woman was referred to the emergency unit for an acute facial rash present for five days. It began on the evening after the first injection of BNT162b2 mRNA COVID-19 vaccine (Pfizer) on the left upper arm. Her past medical history was notable for psoriasis, for which she had recently started guselkumab, a monoclonal antibody directed against interleukin 23 (100 mg, two injections one month apart, with the second injection being given five weeks prior to vaccination). She had never experienced labial herpes. The eruption started on the forehead and extended to the bridge of the nose and the side of the neck. A few sparse lesions were also noted on the lower part of the face and chin (Fig. 1) . She reported puffiness and dusky red periorbital oedema (Fig. 2 ). Upon examination, her clinical presentation was in favour of a herpes virus infection. The patient was in good condition although tired. She denied fever, chills or loss of appetite. She had no headache and no kerato-conjunctivitis, and cranial nerve examination was normal. She had palpable cervical lymph nodes and sensitive preauricular lymph node enlargement. Although the rash was not restricted to one or several dermatomes, we chose to start valaciclovir 1 g t.i.d. for one week. . In our series, two patients were treated with biologics for psoriasis and rheumatoid arthritis, and one patient was treated for myeloma. In the first case, we hypothesize that dissemination of HSV-1 infection may have been related to the immunosuppressive effect of guselkumab, which had not yet reached its peak efficacy. In an Israeli series of patients with autoinflammatory rheumatic diseases, 1.2% of patients (6 of 491) developed HZ two days to two weeks after injection of BNT162b2 mRNA vaccine, compared to no subjects in the control group (n=99). None had ever had HZ previously. HZ was considered mild in most cases, and a second dose of vaccine was given without side effects [6, 9] . HZ can develop after the first or second dose of vaccine [6, 7] . Although vaccination of patients under biologics is mandatory, our first case illustrates that herpes virus reactivation may be more extensive in the event of recent initiation of biologics. Caution is thus warranted wherever initiation of a biotherapy and vaccination are planned concurrently within a short period. We recommend first injecting the initial dose of SARS-CoV-2 vaccine and starting the biotherapy afterwards, wherever the situation allows. Finally, our first patient presented a dusky red periorbital oedema already described in a previous case report and attributed to COVID-19 [11] . While our observation may have been fortuitous, the palpebral redness was striking and the patient did not present this symptom before vaccination.

Interestingly, Mazzatenta et al reported a case of purpura of the eyelids following BTN162b2

Page 5 of 8 J o u r n a l P r e -p r o o f 5 vaccination [12] . Further, cases of chilblains after administration of BNT162b2 vaccine have also been recently described [13, 14] . Immune response to vaccine may trigger symptoms similar to those observed during COVID-19. We felt that our findings were noteworthy and worth reporting in case other colleagues have encountered similar situations. 

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2

Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

Herpes zoster following inactivated COVID-19 vaccine: A coexistence or coincidence?

Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series

Varicella-zoster virus reactivation after SARS

Herpes zoster emergence following mRNA COVID-19 vaccine

Ipsilateral Herpes Zoster after the first dose of BNT162b2 mRNA COVID-19 vaccine

Periorbital erythema as a presenting sign of COVID-19

Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID-19 vaccine: another piece of SARS-CoV-2 skin puzzle?

Pernio after COVID-19 Vaccination

Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that 'COVID toes' are due to the immune reaction to SARS-CoV-2